相关实验视频

Updated: Jul 16, 2025

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

开发一种针对GPR81的新,以抑制脂肪细胞介导的瘤进展

Shaomeng Chen¹, Xiuman Zhou¹, Wanqiong Li¹

¹School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, No. 66, Gongchang Road, Shenzhen 518107, PR China.

Biochemical pharmacology

|September 11, 2023

概括

研究人员发现了一种新的,7w-2,该向GPR81.1. 这种可以抑制脂肪细胞中的脂肪分解,从而抑制小鼠的瘤生长和转移.

科学领域:

生物化学生物化学
免疫学免疫学免疫学
在瘤学瘤学.

背景情况:

G蛋白结合受体81 (GPR81) 抑制脂肪细胞中的脂解.
针对GPR81的现有小分子具有非目标效应和对瘤进展的不确定的影响.
脂肪细胞GPR81在瘤进展中的作用需要进一步研究.

研究的目的:

为了识别和表征一种新的GPR81-向.
评估该在调节脂肪细胞功能和瘤生长方面的有效性.
探索酸对瘤微环境和免疫反应的影响.

主要方法:

菌体显示技术用于选针对GPR81的化物.
鉴定出7w-2的生物活性在体外和体内进行了评估.
评估了瘤细胞增殖,脂肪细胞代谢,脂解,瘤生长,转移以及CD8+ T细胞功能.

主要成果:

素7w-2在体外有效降低了脂肪细胞代谢,抑制了共同培养的瘤细胞的增殖.
在体内,7w-2抑制了脂解,在4T1小鼠模型中显著阻碍了瘤生长和转移.
7w-2增强了CD8+ T细胞的比例和功能.

结论:

7w-2是第一个针对GPR81.1.的鉴定.
脂肪细胞中的GPR81在抑制瘤进展方面发挥作用.
7w-2通过向脂肪细胞代谢和增强抗瘤免疫力,显示出作为癌症治疗的治疗剂的潜力.

关键词:

脂肪细胞脂肪细胞癌症癌症癌症癌症在 GPR81 中使用.脂质溶解脂质溶解是一种这是一种类.

更多相关视频

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Published on: January 7, 2019

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...